These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37167718)

  • 61. Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.
    Van Der Steen N; Keller K; Dekker H; Porcelli L; Honeywell RJ; Van Meerloo J; Musters RJP; Kathmann I; Frampton AE; Liu DSK; Ruijtenbeek R; Rolfo C; Pauwels P; Giovannetti E; Peters GJ
    J Cell Physiol; 2020 Nov; 235(11):8085-8097. PubMed ID: 31960422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.
    Zhao XQ; Xie JD; Chen XG; Sim HM; Zhang X; Liang YJ; Singh S; Talele TT; Sun Y; Ambudkar SV; Chen ZS; Fu LW
    Mol Pharmacol; 2012 Jul; 82(1):47-58. PubMed ID: 22491935
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cloning and characterization of human adenosine 5'-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2).
    Vulevic B; Chen Z; Boyd JT; Davis W; Walsh ES; Belinsky MG; Tew KD
    Cancer Res; 2001 Apr; 61(8):3339-47. PubMed ID: 11309290
    [TBL] [Abstract][Full Text] [Related]  

  • 64. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
    Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
    Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ABCA2 as a therapeutic target in cancer and nervous system disorders.
    Mack JT; Brown CB; Tew KD
    Expert Opin Ther Targets; 2008 Apr; 12(4):491-504. PubMed ID: 18348684
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.
    Boonstra R; Timmer-Bosscha H; van Echten-Arends J; van der Kolk DM; van den Berg A; de Jong B; Tew KD; Poppema S; de Vries EG
    Br J Cancer; 2004 Jun; 90(12):2411-7. PubMed ID: 15150577
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
    Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
    Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutation of ABC transporter ABCA2 confers resistance to Bt toxin Cry2Ab in Trichoplusia ni.
    Yang X; Chen W; Song X; Ma X; Cotto-Rivera RO; Kain W; Chu H; Chen YR; Fei Z; Wang P
    Insect Biochem Mol Biol; 2019 Sep; 112():103209. PubMed ID: 31422154
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma].
    Xie F; Qin X; Tong T; Jiang YY; Zhang JJ
    Shanghai Kou Qiang Yi Xue; 2021 Oct; 30(5):456-461. PubMed ID: 34888594
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
    Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
    J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
    Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells.
    Wang S; Liu C; Lei Q; Wu Z; Miao X; Zhu D; Yang X; Li N; Tang M; Chen Y; Wang W
    Respir Res; 2021 May; 22(1):146. PubMed ID: 33980216
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
    Frederick BA; Helfrich BA; Coldren CD; Zheng D; Chan D; Bunn PA; Raben D
    Mol Cancer Ther; 2007 Jun; 6(6):1683-91. PubMed ID: 17541031
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
    Peng C; Li P; Yang M; Chen D; Huang Y
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):538-547. PubMed ID: 34334155
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner.
    Xiao P; Liu YK; Han W; Hu Y; Zhang BY; Liu WL
    Mol Cancer Res; 2021 Apr; 19(4):726-738. PubMed ID: 33563765
    [TBL] [Abstract][Full Text] [Related]  

  • 77. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
    Hegedüs C; Truta-Feles K; Antalffy G; Várady G; Német K; Ozvegy-Laczka C; Kéri G; Orfi L; Szakács G; Settleman J; Váradi A; Sarkadi B
    Biochem Pharmacol; 2012 Aug; 84(3):260-7. PubMed ID: 22548830
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.
    Wang Y; Wang Y; Qin Z; Cai S; Yu L; Hu H; Zeng S
    Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):291-306. PubMed ID: 33544643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.